Compare Repligen Corporation Common Stock (RGEN) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Skyworks Solutions Inc — how do they compare? Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B), while Skyworks Solutions Inc trades at $76.8 (market cap $18.01B). The key difference: Skyworks Solutions Inc is the larger of the two by market cap, and Skyworks Solutions Inc pays a 4.13% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Skyworks Solutions Inc for 50 Days on average.
| RGEN | SWKS | |
|---|---|---|
Market Cap | $11.14B | $18.01B |
Volume | 1,259,263 | 4,074,606 |
Sector | Health | Technology |
52-Week High | $194.57 | $91.45 |
52-Week Low | $102.87 | $52.50 |
Typical Hold Time | 0 Days | 50 Days |
Enterprise Value | $11.02B | $17.89B |
Dividend Yield | — | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Skyworks Solutions (SWKS) trades at $76.89, up 2.93% with a bearish technical signal despite recent earnings beats. The company shows declining revenue and profit margins over recent years, with 2025 revenue at $4.09B and net income of $477.10M. The pending Qorvo merger dominates news coverage, with analysts projecting significant synergies. Current valuation metrics include a P/E of 39.68 and P/S of 2.87, while cash flow trends show recent negative net cash flow of -$207.30M.
The investment outlook balances merger synergies against fundamental deterioration. Analyst consensus favors Buy (60%) with a $79.70 price target, but declining profitability and bearish technicals suggest caution. Key risks include integration challenges with Qorvo and ongoing margin pressure, while the RSI near 18 indicates potential oversold conditions for tactical opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
